Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis - PubMed (original) (raw)
Review
Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis
David J Grainger. Arterioscler Thromb Vasc Biol. 2004 Mar.
Abstract
The role of the anti-inflammatory cytokine transforming growth factor beta (TGF-beta) in atherosclerosis has been the subject of considerable debate for a decade. In the early 1990s, we postulated that TGF-beta played an important role in maintaining normal vessel wall structure and that loss of this protective effect contributed to the development of atherosclerosis. We termed this the protective cytokine hypothesis. This proposal was slow to gain broad acceptance, however, because at that time there were little data available on the role of TGF-beta during the development of atherosclerosis but much information about its role during trauma-induced neointima formation. Because TGF-beta apparently aggravates neointima formation, both by inhibiting endothelial regeneration and by promoting fibrosis, it was difficult to accept that its presence might ameliorate the superficially similar atherogenesis process. But several recent studies revealed beyond doubt the fact that TGF-beta protects against lipid lesion formation, at least in mouse models of atherosclerosis. Therefore, two important questions remain. First, is the role of TGF-beta in vascular biology similar in humans and in mice? Secondly, how important, compared with defects in thrombosis or lipoprotein metabolism, is the protective role of TGF-beta during atherogenesis?
Comment in
- TGF-beta in atherosclerosis.
Hansson GK, Robertson AK. Hansson GK, et al. Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):E137; author reply E137-8. doi: 10.1161/01.ATV.0000130728.38755.09. Arterioscler Thromb Vasc Biol. 2004. PMID: 15178573 No abstract available.
Similar articles
- The role of transforming growth factor-beta in atherosclerosis.
Singh NN, Ramji DP. Singh NN, et al. Cytokine Growth Factor Rev. 2006 Dec;17(6):487-99. doi: 10.1016/j.cytogfr.2006.09.002. Epub 2006 Oct 23. Cytokine Growth Factor Rev. 2006. PMID: 17056295 Review. - Role of transforming growth factor-beta1/Smads in regulating vascular inflammation and atherogenesis.
Feinberg MW, Jain MK. Feinberg MW, et al. Panminerva Med. 2005 Sep;47(3):169-86. Panminerva Med. 2005. PMID: 16462725 Review. - TGF-beta and atherosclerosis in man.
Grainger DJ. Grainger DJ. Cardiovasc Res. 2007 May 1;74(2):213-22. doi: 10.1016/j.cardiores.2007.02.022. Epub 2007 Feb 23. Cardiovasc Res. 2007. PMID: 17382916 Review. - Targeted disruption of TGF-beta-Smad3 signaling leads to enhanced neointimal hyperplasia with diminished matrix deposition in response to vascular injury.
Kobayashi K, Yokote K, Fujimoto M, Yamashita K, Sakamoto A, Kitahara M, Kawamura H, Maezawa Y, Asaumi S, Tokuhisa T, Mori S, Saito Y. Kobayashi K, et al. Circ Res. 2005 Apr 29;96(8):904-12. doi: 10.1161/01.RES.0000163980.55495.44. Epub 2005 Mar 24. Circ Res. 2005. PMID: 15790953 - TGF-beta1 generates a specific multicomponent extracellular matrix in human coronary SMC.
Schmidt A, Lorkowski S, Seidler D, Breithardt G, Buddecke E. Schmidt A, et al. Eur J Clin Invest. 2006 Jul;36(7):473-82. doi: 10.1111/j.1365-2362.2006.01658.x. Eur J Clin Invest. 2006. PMID: 16796604
Cited by
- Development of Pro-resolving and Pro-efferocytic Nanoparticles for Atherosclerosis Therapy.
Patel Y, Manturthi S, Tiwari S, Gahunia E, Courtemanche A, Gandelman M, Côté M, Gadde S. Patel Y, et al. ACS Pharmacol Transl Sci. 2024 Sep 13;7(10):3086-3095. doi: 10.1021/acsptsci.4c00292. eCollection 2024 Oct 11. ACS Pharmacol Transl Sci. 2024. PMID: 39416959 - Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors.
Gergely TG, Drobni ZD, Sayour NV, Ferdinandy P, Varga ZV. Gergely TG, et al. Basic Res Cardiol. 2024 Jul 17. doi: 10.1007/s00395-024-01068-8. Online ahead of print. Basic Res Cardiol. 2024. PMID: 39023770 Review. - SMAD3 rs17228212 Polymorphism Is Associated with Advanced Carotid Atherosclerosis in a Slovenian Population.
Petrovič D, Letonja J, Petrovič D. Petrovič D, et al. Biomedicines. 2024 May 16;12(5):1103. doi: 10.3390/biomedicines12051103. Biomedicines. 2024. PMID: 38791063 Free PMC article. - Association between Immune Checkpoint Inhibitors and Atherosclerotic Cardiovascular Disease Risk: Another Brick in the Wall.
Piras L, Zuccanti M, Russo P, Riccio F, Agresti A, Lustri C, Dardani D, Ferrera A, Fiorentini V, Tocci G, Tini Melato G, Volpe M, Barbato E, Battistoni A. Piras L, et al. Int J Mol Sci. 2024 Feb 21;25(5):2502. doi: 10.3390/ijms25052502. Int J Mol Sci. 2024. PMID: 38473748 Free PMC article. Review. - Decreased circulating transforming growth factor-beta (TGF-β) and kidney TGF-β immunoreactivity predict renal disease in cats with naturally occurring chronic kidney disease.
Piyarungsri K, Chuammitri P, Pringproa K, Pila P, Srivorakul S, Sornpet B, Pusoonthornthum R. Piyarungsri K, et al. J Feline Med Surg. 2023 Dec;25(12):1098612X231208937. doi: 10.1177/1098612X231208937. J Feline Med Surg. 2023. PMID: 38131312 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources